MECP2 and myelodysplastic syndrome: In the severe Tg3 MDS model (which expresses 3 to 5-fold the endogenous MeCP2 levels), isoform-selective silencing produced initial improvements in phenotypes but failed to achieve long-term disease modification with a single administration, while total MECP2 silencing modified disease for at least one year following a single administration.